Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 5 patents
16 readers on Mendeley
  • Article usage
  • Citations to this article (110)

Advertisement

Research Article Free access | 10.1172/JCI117089

Cyclosporin A inhibits CD40 ligand expression in T lymphocytes.

R Fuleihan, N Ramesh, A Horner, D Ahern, P J Belshaw, D G Alberg, I Stamenkovic, W Harmon, and R S Geha

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Fuleihan, R. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Ramesh, N. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Horner, A. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Ahern, D. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Belshaw, P. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Alberg, D. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Stamenkovic, I. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Harmon, W. in: JCI | PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Geha, R. in: JCI | PubMed | Google Scholar

Published March 1, 1994 - More info

Published in Volume 93, Issue 3 on March 1, 1994
J Clin Invest. 1994;93(3):1315–1320. https://doi.org/10.1172/JCI117089.
© 1994 The American Society for Clinical Investigation
Published March 1, 1994 - Version history
View PDF
Abstract

The ligand for CD40 is expressed on activated T lymphocytes and delivers contact-dependent activation signals to B lymphocytes. The mechanisms regulating CD40 ligand gene expression are largely unknown. Optimal expression of CD40 ligand required activation of protein kinase C and a rise in intracellular calcium concentration. CD40 ligand expression was inhibited by pretreatment of T cells with cyclosporin A. Cyclosporin A analogues inhibited CD40 ligand expression with a potency mirroring the ability of each compound to inhibit calcineurin activity, indicating that calcineurin plays a key role in CD40 ligand gene expression. Cyclosporin A inhibited IL-4-driven CD40 ligand-dependent IgE isotype switching in PBMC but did not inhibit IgE synthesis induced by CD40 mAb plus IL-4. PBMC derived from transplant patients receiving cyclosporin A failed to express CD40 ligand upon stimulation. These results suggest that patients receiving cyclosporin A may be deficient in CD40 ligand-dependent T cell help.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1315
page 1315
icon of scanned page 1316
page 1316
icon of scanned page 1317
page 1317
icon of scanned page 1318
page 1318
icon of scanned page 1319
page 1319
icon of scanned page 1320
page 1320
Version history
  • Version 1 (March 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (110)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
16 readers on Mendeley
See more details